SCHEMBL2797249

SCHEMBL2797249

COC(=O)C(C)c1c(Cl)ncnc1Cl

nearest known ligand 0.39

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 1/20 0.35
PTGS1 P23219 1/20 0.34
PTGS2 P35354 1/20 0.34
KMT2A Q03164 3/20 0.33
L3MBTL1 Q9Y468 2/20 0.33
MEN1 O00255 2/20 0.33
MAPT P10636 1/20 0.33
ALDH1A1 P00352 2/20 0.33
SMN1; SMN2 Q16637 2/20 0.32
HPGD P15428 1/20 0.32
MT-CO2 P00403 1/20 0.32
FGFR1 P11362 2/20 0.32
FGFR4 P22455 2/20 0.32
LMNA P02545 2/20 0.31
AURKA O14965 1/20 0.31
CA12 O43570 1/20 0.31
CA1 P00915 1/20 0.31
CA2 P00918 1/20 0.31
CA9 Q16790 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8707605 0.89 HSD17B10 (0.33) MAPK1PTGS1PTGS2KMT2AL3MBTL1
SCHEMBL8708452 0.79 MT-CO2 (0.36) PTGS1PTGS2KMT2AL3MBTL1ALDH1A1
SCHEMBL22308707 0.74 ALDH1A1 (0.38) MAPK1L3MBTL1ALDH1A1SMN1; SMN2FGFR1
SCHEMBL15391066 0.74 MAPT (0.37) PTGS2KMT2AL3MBTL1MAPTALDH1A1
SCHEMBL1662205 0.74 MAPT (0.37) PTGS2KMT2AL3MBTL1MAPTALDH1A1
SCHEMBL8706888 0.73 PTGS2 (0.33) MAPK1PTGS1PTGS2KMT2AMEN1
SCHEMBL5786719 0.72 PTGS1 (0.45) PTGS1PTGS2KMT2AALDH1A1HPGD
SCHEMBL29137732 0.70 PTGS1 (0.41) MAPK1PTGS1PTGS2KMT2AL3MBTL1
SCHEMBL18148764 0.70 PTK2 (0.44) MAPK1KMT2AL3MBTL1MEN1HPGD
SCHEMBL1662668 0.69 MAPK1 (0.33) MAPK1KMT2AL3MBTL1MEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-117157297-A PRMT5 inhibitors 上海齐鲁制药研究中心有限公司 2023-12-01 CN disclosed
WO-2023001133-A1 PRMT5 INHIBITOR 上海齐鲁制药研究中心有限公司 2023-01-26 WO disclosed
WO-2023001133-A1 PRMT5 INHIBITOR 上海齐鲁制药研究中心有限公司 2023-01-26 WO disclosed
EP-3459953-B1 NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE TAIHO PHARMACEUTICAL CO LTD (JP) 2021-06-30 EP disclosed
CN-109153681-B Novel 5H-pyrrolo [2,3-d ] pyrimidin-6 (7H) -one derivatives 大鹏药品工业株式会社 2021-06-04 CN disclosed
US-20190292190-A1 NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE TAIHO PHARMACEUTICAL CO., LTD. (JP) 2019-09-26 US disclosed
EP-3459953-A1 NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE Taiho Pharmaceutical Co., Ltd. (JP) 2019-03-27 EP disclosed
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2016-06-02 US disclosed
US-20140148436-A1 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA, INC. (US) 2014-05-29 US disclosed
US-8680114-B2 AKT protein kinase inhibitors ARRAY BIOPHARMA, INC. (US) 2014-03-25 US disclosed
US-20100168123-A1 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. 2010-07-01 US disclosed
EP-1684694-A2 AKT PROTEIN KINASE INHIBITORS Array Biopharma, Inc. (US) 2006-08-02 EP disclosed
US-20050130954-A1 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline ARRAY BIOPHARMA INC. 2005-06-16 US disclosed
WO-2005051304-A2 AKT PROTEIN KINASE INHIBITORS ARRAY BIOPHARMA INC. (US) 2005-06-09 WO disclosed
US-5783580-A FUNGICIDES SANDOZ, LTD. (CH) 1998-07-21 US disclosed
US-5547919-A CONTROLLING PHYTOPATHOGENIC FUNGI SANDOZ LTD. (CH) 1996-08-20 US disclosed
EP-0667343-A1 Alpha-pyrimidinyl acrylic acid derivatives with fungicidal activity SANDOZ LTD. (CH) 1995-08-16 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100168123-A1 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 MAPK1 65/4885PTGS1 3828/4885PTGS2 4054/4885
US-20140148436-A1 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 MAPK1 65/4885PTGS1 3828/4885PTGS2 4054/4885
US-20160152576-A9 AKT PROTEIN KINASE INHIBITORS AKT1, AKT2, AKT3 MAPK1 65/4885PTGS1 3828/4885PTGS2 4054/4885
US-20050130954-A1 Serine/threonine protein kinase inhibitors; hyperproliferative disorder or inflammatory conditions; e.g. 4-(4-(2-amino-3-(p-chlorophenyl)-propionyl)-piperazin-1-yl)-quinazoline MTOR, CDK2, CLK2 MAPK1 98/4885PTGS1 1928/4885PTGS2 2578/4885
US-20190292190-A1 NOVEL 5H-PYRROLO[2,3-D]PYRIMIDIN-6(7H)-ONE DERIVATIVE RPS6KA1, RPS6KA3, MAPK9 MAPK1 39/4885PTGS1 2012/4885PTGS2 2509/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.